Sectors
MLTX
MoonLake Immunotherapeutics
19.39
1 x 19.36
3 x 19.44
bid
ask
-
0.67
3.34%
10:02 AM
timesize
| Ytd | 47.12% | |
| 1y | -63.80% |
19.57
day range
20.00
5.95
52 week range
62.75
| Open | 19.90 | Prev Close | 20.06 | Low | 19.57 | High | 20.00 | Mkt Cap | 1.66B |
| Vol | 171.78K | Avg Vol | 1.10M | EPS | -3.87 | P/E | -5.18 | Forward P/E | -5.94 |
| Beta | 1.04 | Short Ratio | 5.02 | Inst. Own | 79.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.86 | 200-d Avg | 15.78 | 1yr Est | 28.00 |
| Income Statement | |||
| Operating Expenses | 70.02M | ||
| Research and Development Expense | 54.52M | ||
| Selling, General and Administrative Expense | 15.51M | ||
| Operating Income | -70.02M | ||
| Interest Expense | 2.27M | ||
| Income Tax Expense | 622.00K | ||
| Net Income | -69.71M | ||
| Net Income Common Stock | -69.71M | ||
| Net Income Common Stock (USD) | -69.71M | ||
| Consolidated Income | -69.71M | ||
| Earnings per Basic Share | -0.98 | ||
| Earnings per Basic Share (USD) | -0.98 | ||
| Earnings per Diluted Share | -0.98 | ||
| Earning Before Interest & Taxes (EBIT) | -66.82M | ||
| Earning Before Interest & Taxes (USD) | -66.82M | ||
| Weighted Average Shares | 71.27M | ||
| Weighted Average Shares Diluted | 71.27M | ||
| Balance Sheet | |||
| Cash and Equivalents | 298.49M | ||
| Cash and Equivalents (USD) | 298.49M | ||
| Investments | 59.43M | ||
| Investments Current | 59.43M | ||
| Trade and Non-Trade Receivables | 5.76M | ||
| Current Assets | 396.64M | ||
| Property, Plant & Equipment Net | 2.39M | ||
| Total Assets | 400.37M | ||
| Debt Current | 920.00K | ||
| Total Debt | 100.80M | ||
| Current Liabilities | 46.11M | ||
| Debt Non-Current | 99.88M | ||
| Total Liabilities | 146.35M | ||
| Accumulated Retained Earnings (Deficit) | -532.62M | ||
| Accumulated Other Comprehensive Income | 322.00K | ||
| Shareholders Equity | 254.02M | ||
| Shareholders Equity (USD) | 254.02M | ||
| Assets Non-Current | 3.73M | ||
| Total Debt (USD) | 100.80M | ||
| Liabilities Non-Current | 100.24M | ||
| Trade and Non-Trade Payables | 23.38M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 845.00K | ||
| Net Cash Flow from Financing | 30.64M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -36.03M | ||
| Issuance (Purchase) of Equity Shares | 6.18M | ||
| Issuance (Repayment) of Debt Securities | 24.47M | ||
| Net Cash Flow from Investing | 98.00K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 98.00K | ||
| Net Cash Flow from Operations | -66.29M | ||
| Effect of Exchange Rate Changes on Cash | -483.00K | ||
| Share Based Compensation | 13.36M | ||